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Abstract
Purpose Pharmacokinetics and effects on skeletal muscle
and physical performance of oral acetylcarnitine and pro-
pionylcarnitine are not well characterized. We therefore
investigated the influence of oral acetylcarnitine, propio-
nylcarnitine, and carnitine on body carnitine homeostasis,
energy metabolism, and physical performance in mice and
compared the findings to non-supplemented control
animals.
Methods Mice were supplemented orally with 2 mmol/
kg/day carnitine, acetylcarnitine, or propionylcarnitine for
4 weeks and studied either at rest or after exhaustive
exercise.
Results In the supplemented groups, total plasma and
urine carnitine concentrations were significantly higher
than in the control group receiving no carnitine, whereas
the skeletal muscle carnitine content remained unchanged.
The supplemented acylcarnitines were hydrolyzed in
intestine and liver and reached the systemic circulation as
carnitine. Bioavailability of carnitine and acylcarnitines,
determined as the urinary excretion of total carnitine, was
in the range of 19 %. Skeletal muscle morphology,
including fiber-type composition, was not affected, and
oxygen consumption by soleus or gastrocnemius fibers was
not different between the groups. Supplementation with
carnitine or acylcarnitines had no significant impact on the
running capacity, but was associated with lower plasma
lactate levels and a higher glycogen content in white
skeletal muscle after exhaustive exercise.
Conclusions Oral supplementation of carnitine, acetyl-
carnitine, or propionylcarnitine in mice is associated with
increased plasma and urine total carnitine concentrations,
but does not affect the skeletal muscle carnitine content.
Despite better preservation of skeletal muscle glycogen and
lower plasma lactate levels, physical performance was not
improved by carnitine or acylcarnitine supplementation.
Keywords Carnitine and short-chain acylcarnitines 
Bioavailability  Muscle composition and metabolism 
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Introduction
Carnitine is an amino acid derivative playing an essential
role in cellular energy metabolism due to the acylation of
its b-hydroxyl group. Carnitine is essential for the transport
of long-chain fatty acids into the mitochondrial matrix
[17], where they undergo b-oxidation. In addition, carnitine
also acts as a buffer of the cellular pool of free coenzyme A
(CoASH) [8, 16]. The major carnitine pool, accounting
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for [ 95 % of the total body stores, is located in skeletal
muscle [22, 38].
Taking into account these important functions of car-
nitine, it is not surprising that carnitine supplementation
has been studied intensively as a potential performance
enhancer [6]. In ex vivo models, it has been reported that
an elevation of the carnitine muscle content increases
skeletal muscle force and delays fatigue [9, 14]. In humans,
however, most studies failed to show a positive effect of
carnitine supplementation on physical performance. This
finding correlates with the fact that, despite elevated
plasma concentrations, the skeletal muscle carnitine con-
tent could not be increased by oral or parenteral carnitine
supplementation
High oral doses of carnitine during several days or
intravenous infusion before exercise failed to show an
impact on the physical performance of healthy volunteers
or athletes [4, 31, 43]. Recently, however, Wall and col-
leagues reported an approximately 20 % increase in the
carnitine muscle content in human subjects ingesting 80 g
carbohydrate and 2 g carnitine tartrate per day [45]. This
increase in the skeletal muscle carnitine content was
associated with enhanced work output and maintained
skeletal muscle glycogen stores as well as reduced lactate
production during exercise.
Rodent studies investigating carnitine accumulation in
skeletal muscle during or after carnitine supplementation
led to controversial results. In several studies, an increase
in the skeletal muscle carnitine content in supplemented
rats was reported [2, 12, 21, 29, 40], whereas in other
investigations in rats [24] or mice [34], no such increase
could be detected. While the effect of exogenous carnitine
on the carnitine skeletal muscle pool of rodents has been
investigated intensively, studies about the effect of short-
chain acylcarnitines, e.g., acetylcarnitine or propionylcar-
nitine, on the skeletal muscle carnitine content and mor-
phology as well as on physical performance are rare. To the
best of our knowledge, the pharmacokinetics of orally
administered acetyl- and propionylcarnitine have so far not
been described in detail. In humans, both acetylcarnitine
[32] and propionylcarnitine [44] can intestinally be absor-
bed and can reach the systemic circulation, but the bio-
availability is not known. In pigs, the relative
bioavailability of oral acetylcarnitine (determined as free
carnitine) was 61 % compared to L-carnitine [15]. In
rodents, pharmacokinetic data are so far lacking for oral
acetyl- and propionylcarnitine, but systemic effects have
been described for both acylcarnitines [26], suggesting that
intestinal absorption is possible. For carnitine, it has been
shown that increased plasma concentrations are not nec-
essarily associated with an increase in the skeletal muscle
carnitine pool [7]. This can be explained by saturation of
the transport into skeletal muscle already at physiological
carnitine plasma concentrations [5] and by a much higher
carnitine concentration in skeletal muscle compared to
plasma [7, 16], rendering passive transport impossible. In
comparison with carnitine, skeletal muscle concentrations
of acetylcarnitine and propionylcarnitine are much lower
under resting conditions. Similar to plasma, the acetylcar-
nitine concentration in skeletal muscle is in the range of
20 % of the free carnitine concentrations [16, 27], whereas,
to the best of our knowledge, skeletal muscle propionyl-
carnitine concentrations have so far not been reported. In
human plasma, the propionylcarnitine concentration is in
the range of 0.5 mM [28]. Taking into account that short-
chain acylcarnitines can cross biological membranes by
passive diffusion [25], it might be possible to transport
acetyl- and propionylcarnitine into skeletal muscle, if their
plasma concentrations could be increased sufficiently.
In order to answer some of the open questions discussed
above, we supplemented mice orally with high doses of
carnitine, acetylcarnitine, or propionylcarnitine during
4 weeks, subjected some of them to exhaustive exercise
and analyzed the carnitine pools and metabolic markers in
skeletal muscle, plasma, and urine both at rest and after
exhaustive exercise. The study was also designed to assess
oral bioavailability of carnitine and acylcarnitines as well
as the impact of carnitine supplementation skeletal muscle
morphology and ex vivo oxidative capacity.
Materials and methods
Animals
The experiments were performed in agreement with the
guidelines for the care and use of laboratory animals and
were approved by the cantonal veterinary authority
(License 2509). The animals were adult age-matched male
C57BL/6 mice (Janvier, Le Genest-Saint-Isle, France),
housed in a standard facility with 12-h light–dark cycles
and controlled temperature (21–22 C). The mice were fed
with a standard pellet chow and water ad libitum. After
7 days of acclimatization, the mice were divided into four
groups of 12 animals each: (1) Control group, (2) Carnitine
group, (3) Acetylcarnitine group (Acetyl-Cn), and (4)
Propionylcarnitine group (Propionyl-Cn). Half of the ani-
mals of each group (n = 6) were housed for 24 h in a
metabolic cage for urine collection and performed an
exhaustive exercise before killing (see below).
Carnitine or acylcarnitine supplementation
L-Carnitine and acetyl-L-Carnitine HCl were purchased
from Sigma (St. Louis, MO, USA). Propionyl-L-Carnitine
HCl was a kind gift of Sigma Tau (Pomezia, Rome, Italy).
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The solutions of carnitine, acetylcarnitine, and propionyl-
carnitine were made in tap water once a week and were
kept at 4 C until use. After 1 week of acclimatization, the
mice were supplemented with carnitine, acetylcarnitine, or
propionylcarnitine via drinking water for 4 weeks. Carni-
tine and carnitine derivatives concentration in tap water
were 10 mmol/L so that mice of about 25 g drinking 5 mL/
day would be exposed to approximately 2 mmol/kg/day of
each compound. Water consumption was monitored daily
(see ‘‘Results’’). Carnitine content in the standard chow and
in the drinking water was determined using liquid chro-
matography–tandem mass spectrometry (LC–MS/MS) as
previously described [28]. The mice received a standard
pellet chow ad libitum (Kliba Futter 3436, Basel, Swit-
zerland) with a carnitine content of 60 nmol/g.
Protocol
Between week 1 and 2 of supplementation, the mice spent
24 h individually in metabolic cages with supplemented
water and food ad libitum. During this period, 24-h urine
was collected to assess the excretion of carnitine and
acylcarnitines.
After 4 weeks of supplementation, the mice were sub-
mitted to an exhaustive exercise on a treadmill with pre-
vious acclimatization to the apparatus (Exer-3/6, Columbus
Instruments, Columbus, OH, USA). Two days and 1 day
before initiation of the study, each mouse underwent a five-
minute training session at a speed of 5 m/min. On the day
of killing, the starting speed was 5 m/min; after 5 min, the
speed was increased by 1 m/min every minute until the
maximal speed of 20 m/min was reached. The rear of the
treadmill was equipped with low-voltage, electric-stimu-
lating grids, to encourage the mice to run. The grid deliv-
ered 0.4 mA at a frequency of 2 Hz, which caused an
uncomfortable shock without injuring the animal.
Exhaustion was defined as immobility for more than 5 s on
the end lane grid despite electric stimulation.
Physical performance of the mice was calculated from
the distance and the duration of the run according to the
following equation:
PerformanceðwÞ ¼ m ðkgÞ  a m=s
2ð Þ  d ðmÞ
t ðsÞ ð1Þ
with m being the mass of the animal, a the gravitational
acceleration, d the running distance, and t the running time.
Biological sample collection
After exhaustion, the mice were immediately anaesthetized
with an intraperitoneal application of ketamine
(100 mg/kg) and xylazine (10 mg/kg). The soleus and the
superficial part of the gastrocnemius muscles were excised
and conserved in ice-cold BIOPS buffer (10 mmol/L Ca-
EGTA buffer, 0.1 lmol/L free calcium, 5.77 mmol/L ATP,
6.56 mmol/L MgCl2, 20 mmol/L taurine, 15 mmol/L
phosphocreatine, 0.5 mmol/L dithiothreitol, and 50 mmol/
L K-MES, pH 7.1) until analysis.
For chemical analysis, muscle samples—red and white
quadriceps biopsies—and liver samples were frozen in
liquid nitrogen immediately after excision. Since the mice
were anesthetized, tissues were obtained from living ani-
mals and the time between sampling and freezing was only
a few seconds.
Blood was collected into heparin-coated tubes by an
intracardiac puncture or a tail incision. Plasma was sepa-
rated by centrifugation at 3,000g for 15 min. Plasma, urine,
liver, and muscle samples were kept at -80 C until
analysis.
Carnitine and acylcarnitine bioavailability
and biosynthesis
Carnitine and acylcarnitine bioavailability (F) and bio-
synthesis were calculated by solving equation for F or
biosynthesis, respectively (2). Equation (2) represents the
mass balance of carnitine and acylcarnitines, assuming that
carnitine or acylcarnitine inputs into mice have to equal
tissue accumulation plus carnitine excretion:
F  intakewater þ intakefoodð Þ þ biosynthesis
¼ tissue accumulation þ excretion ð2Þ
Carnitine tissue accumulation was estimated using the
average of the carnitine content of red and white muscle as
the skeletal muscle carnitine content and assuming that
skeletal muscle equals 35 % of the body weight in rodents
[22]. Since skeletal muscle contains [90 % of tissue
carnitine [22, 38], only the skeletal muscle carnitine
content was used for estimating tissue accumulation.
Carnitine excretion was determined using the 24-h urine
samples obtained as described above. Carnitine intake by
water or food was calculated by multiplying the amount of
water or food ingested with the respective carnitine
concentration.
F was calculated first for the mice treated with exoge-
nous carnitine or acylcarnitines by solving Eq. (2) for F and
assuming that intake of carnitine by food or water is much
larger than carnitine biosynthesis [22]. The value for F
obtained for mice treated with carnitine was then used to
calculate carnitine biosynthesis in control mice using
Eq. (2).
Skeletal muscle oxidative capacity
Mitochondrial respiration measured in situ allows the
characterization of functional mitochondria in their normal
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intracellular position and assembly, preserving essential
interactions with other organelles. Mitochondrial oxygen
consumption was studied in saponin-skinned fibers [23].
Fibers were separated under a binocular microscope in
BIOPS buffer at 4 C. After dissection, fibers were trans-
ferred into BIOPS buffer containing 50 lg/mL saponin and
incubated at 4 C for 30 min while shaking to complete
permeabilization of the sarcolemma. Permeabilized fibers
were then washed in BIOPS buffer for 10 min under
intense shaking to completely remove saponin. Before
oxygraphic measurements, the fibers were washed twice
for 5 min in MiR05 buffer (EGTA 0.5 mmol/L, MgCl2
3 mmol/L, taurine 20 mmol/L, KH2PO4 10 mmol/L,
HEPES 20 mmol/L, D-sucrose 110 mmol/L, BSA essen-
tially fatty acid free 1 g/L, and lactobionic acid 60 mmol/
L) to remove any trace amount of high-energy phosphates.
All oxygen measurements were taken at 37 C with an
Oxygraph 2 k apparatus equipped with the Datlab software
(OROBOROS, Innsbruck, Austria) [33]. Per respiration
chamber, 1–2 mg of permeabilized fibers was added to
2.0 mL of MiR05 buffer.
The following protocol was used to evaluate the activity
of the different mitochondrial complexes. The rate of basal
respiration was measured with the complex I substrates
glutamate (10 mM) and malate (2 mM), whereas active
respiration was induced with 2 mM ADP. After inhibition
of complex I with 0.5 mM rotenone, respiration was
restored with the addition of complex II substrate succinate
(10 mM). Inhibition of complex II with 20 mmol/L mal-
onate was followed by the addition of the artificial sub-
strates for complex IV, TMPD (0.5 mM), and ascorbate
(2 mM). To verify the integrity of the outer mitochondrial
membrane, cytochrome c (10 lmol/L) was added at the
end of the respiration protocol. Respiration rates are
expressed in picomoles O2 per second per gram wet
weight.
Skeletal muscle histology
Muscle biopsies for histological imaging were frozen in
isopentane cooled in liquid nitrogen. Ten-micrometer serial
sections were cut from the soleus and gastrocnemius
muscle on a cryostat microtome (HYRAX C60, Carl Zeiss
Microscopy, Jena, Germany) and mounted on glass slides.
The histological structure of muscular fibers was deter-
mined by a routine hematoxylin/eosin staining. Soleus and
gastrocnemius fiber-type composition was determined by
histochemical staining of the myosin ATPase activity [3].
Stained fibers at pH 9.4 were counted from two non-
overlapping visual fields using a microscope (Olympus
BX43, Olympus corporation, Tokyo, Japan) at a 100-fold
magnification. Quantification was performed with an
empirically calibrated thresholding macro in imageJ [35],
classifying and counting each pixel as either background,
light or dark fibers, based on two cutoff values.
Urinary carnitine concentrations
A LC–MS/MS method previously described was adapted
for the determination of carnitine and acylcarnitines in
urine [28]. The method was extended to the analysis of
propionylcarnitine (transitions 218/85 and 218/159) and
creatinine (114/44 and 114/86). Hydrolysis of total carni-
tine was achieved with 0.5 mol/L potassium hydroxide,
neutralization, and dilution with 0.1 % formic acid.
Plasma parameters
Plasma concentrations of carnitine were determined as
previously described with adaptation to propionylcarnitine
[28]. Venous lactate concentrations were analyzed with an
enzymatic assay [30]. Creatine kinase activity in venous
plasma was determined before and after exhaustive exer-
cise with a kit according to the supplier’s instructions
(BioAssay Systems, Hayward, CA, USA).
Skeletal muscle and liver parameters
Muscle tissue was homogenized with a Micro-dismem-
brator during 1 min at 2,000 rpm (Sartorius Stedim Bio-
tech, Go¨ttingen, Germany). About 50 mg muscle was
extracted with 1 mL of extracting solvent depending on the
metabolites determined as described below. Liver tissue
was homogenized during 30 s at 2,000 rpm and then
extracted with 1 mL methanol per 100 mg tissue.
Phosphocreatine, creatine, and ATP were determined
photometrically in an acidic extract (perchloric acid
0.5 mol/L, EDTA 1 mmol/L) of muscle powder as
described [18]. Muscle glycogen content was analyzed in
alkaline (NaOH 0.1 mmol/L) muscle extracts according to
Harris [18]. Carnitine, acylcarnitines, and total carnitine
were determined in aqueous muscle extracts with an
established LC–MS/MS method [28]. This assay had an
interassay precision of \6.0 % for all measured analytes,
and the interday accuracies were between 92.9 and
105.5 %.
Statistical analysis
Data are expressed as mean ± SEM. Comparisons of two
groups were performed using the unpaired two-tailed Stu-
dent’s t test. Multiple groups were compared using either
one-way ANOVA or two-way ANOVA both followed by a
Dunnett posttest. The software used was Prism version 5
(Graph Pad Software, San Diego, CA). Groups supple-
mented with carnitine or acylcarnitines were compared
1316 Eur J Nutr (2014) 53:1313–1325
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individually with the untreated control group. For certain
analyses, the groups treated with carnitine or acylcarnitines
were also pooled for the comparison with the control
group. Statistical significance was set at *p \ 0.05.
Results
Characterization of the animals
During the study, the daily food intake was similar in all
groups (mean ± SEM; 4.04 ± 0.18 g in the control group,
4.14 ± 0.27 g in the carnitine, 3.81 ± 0.41 g in the acetyl-
carnitine and 4.17 ± 0.12 g in the propionylcarnitine group)
and we observed no weight differences between the groups
(Fig. 1a). The body weight gain (mean ± SEM) was
2.78 ± 0.23 g in the control group, 3.26 ± 0.28 g in the
carnitine, 3.10 ± 0.42 g in the acetylcarnitine, and
3.37 ± 0.24 g in the propionylcarnitine group. In contrast,
the daily water intake was significantly increased in all
groups treated with carnitine or acylcarnitines compared to
the control group (Fig. 1b). The control animals (n = 12)
drank 4.1 ± 0.2 mL/day, whereas the animals of the carni-
tine, acetylcarnitine, and propionylcarnitine group ingested
5.2 ± 0.1 mL/day, 5.7 ± 0.3 mL/day, and 5.6 ± 0.1 mL/
day, respectively (mean ± SEM; no difference between
treated animals). The mean daily exposure to exogenous
carnitine, acetylcarnitine, or propionylcarnitine was
2.2 mmol/kg/day (range 1.9–2.7 mmol/kg/day) in the trea-
ted groups and below 10 lmol/kg/day in the control group,
taking into account the carnitine ingested in drinking water
and in food (Fig. 1c). Concentrations of carnitine, acetyl-
carnitine, and propionylcarnitine in drinking solutions
remained stable during their storage at 4 C and in the water
bottles at room temperature (data not shown).
Carnitine and acylcarnitine pools in plasma, liver,
and skeletal muscle and renal carnitine excretion
In plasma, total carnitine concentrations were 17–31 %
higher in the treated groups compared to control animals,
reaching statistical significance for all treatments (Table 1).
This increase was mainly due to elevated free carnitine
concentrations, whereas acetylcarnitine and palmitoylcar-
nitine plasma concentrations were similar between the
groups. The propionylcarnitine concentration was approx-
imately three times higher in mice treated with propio-
nylcarnitine compared to the other groups but without
reaching statistical significance.
In red or white skeletal muscle, we observed no differ-
ence in carnitine pools between the groups treated with
carnitine or acylcarnitines and the control group.
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Fig. 1 Characterization of the
animals. The weight gain (in
grams) was similar in the
treatment groups compared to
control (a). Water consumption
(in mL/mouse/day) was
significantly higher in the
treated groups (b). Daily
consumption of carnitine or
acylcarnitines was below
10 lmol/kg/day in the control
group and in the range of
2,000 lmol/kg/day in the
supplemented groups (c). Data
are represented as
mean ± SEM of 12 animals per
group
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Acetylcarnitine concentrations accounted for 20 % of total
pool in red fibers and for 15 % in white fibers. Total car-
nitine, free carnitine, acetylcarnitine, and palmitoylcarni-
tine concentrations were by trend lower in the white
compared to the red quadriceps. Propionylcarnitine con-
centrations in skeletal muscle were below detection limits
(\0.5 lmol/kg), also in mice treated with propionylcarni-
tine (Table 1).
In liver samples of animals supplemented with propio-
nylcarnitine, the free carnitine content (vs. non-supple-
mented control animals) was 449 ± 46 versus
314 ± 16 lmol/kg (p \ 0.05), the acetylcarnitine content
231 ± 22 versus 195 ± 8 lmol/kg (not significant), and
the propionylcarnitine content 4.7 ± 0.5 versus
3.1 ± 0.2 lmol/kg (p \ 0.05).
Mice treated with carnitine or acylcarnitines excreted
16–18 times more total carnitine than control animals
(Table 2). The major part of excreted carnitine was found in
the form of free carnitine and acetylcarnitine. In all treated
groups, independently of the supplemented form of carni-
tine, carnitine and acetylcarnitine excretion was significantly
higher than in the untreated control group. Urinary excretion
of propionylcarnitine could only be detected in the three
supplemented groups, whereas propionylcarnitine concen-
trations were below detection limits in urine of control mice.
The highest urinary propionylcarnitine excretion was found
in the group treated with propionylcarnitine. Due to the high
variability, this value was not significantly different from the
propionylcarnitine concentration in the urines of mice trea-
ted with carnitine or acetylcarnitine.
Ingestion and bioavailability of carnitine
and acylcarnitines and carnitine biosynthesis
Total carnitine ingestion, bioavailability, and biosynthesis
are presented in Table 3. Total carnitine intake was
approximately 200 times higher in animals supplemented
with carnitine, acetylcarnitine, or propionylcarnitine as
compared to untreated control animals. Carnitine tissue
accumulation, calculated from the mean total carnitine
concentration in red and white muscles and from the
muscle weight gain during the observation period of
1 month, was not different between the groups and was
quantitatively negligible compared to oral ingestion of
carnitine. Excretion of total carnitine was, as mentioned in
the previous section, 16–18 times higher in the treated
groups as compared to the control group. Carnitine bio-
availability, calculated according to Eq. 2 and assuming
that carnitine biosynthesis is much lower than the ingestion
of exogenous carnitine or acylcarnitines by the drinking
water, ranged between 18.6 and 19.8 % for carnitine and
acylcarnitines without a significant difference between the
supplemented groups. It is important to realize that bio-
availability was calculated from the urinary excretion of
carnitine (also for the acylcarnitines), since the acylcarni-
tines were hydrolyzed in the gut and/or the liver and
reached the systemic circulation only in the form of car-
nitine. Carnitine biosynthesis, calculated for control mice
using Eq. (2) and the value for carnitine bioavailability
obtained for mice treated with carnitine, was in a similar
range as reported for rats [22].
Table 1 Concentrations of
carnitine and acylcarnitines in
plasma and skeletal muscle
under resting conditions
Mean values ± SEM of six
animals are represented
* p \ 0.05 compared to control
Control Carnitine Acetyl-Cn Propionyl-Cn
Plasma concentrations (lmol/L)
Carnitine 31.0 ± 0.5 37.2 ± 2.2 36.1 ± 1.4 35.6 ± 3.4
Acetylcarnitine 7.8 ± 0.8 8.5 ± 1.3 9.3 ± 0.6 7.6 ± 0.7
Propionylcarnitine 0.30 ± 0.04 0.24 ± 0.07 0.27 ± 0.04 0.76 ± 0.38
Palmitoylcarnitine 0.25 ± 0.01 0.29 ± 0.04 0.25 ± 0.02 0.30 ± 0.03
Total carnitine 36.4 ± 1.4 47.7 ± 1.8* 47.6 ± 1.6* 42.7 ± 1.6*
Skeletal muscle concentrations (lmol/kg wet weight)
Red quadriceps
Free carnitine 205 ± 29 272 ± 32 216 ± 25 189 ± 14
Acetylcarnitine 66 ± 7 69 ± 11 70 ± 3 62 ± 9
Propionylcarnitine \0.5 \0.5 \0.5 \0.5
Palmitoylcarnitine 44 ± 8 55 ± 6 32 ± 12 28 ± 5
Total carnitine 291 ± 31 309 ± 59 359 ± 56 249 ± 43
White quadriceps
Free carnitine 110 ± 7 115 ± 10 127 ± 11 130 ± 11
Acetylcarnitine 39 ± 5 37 ± 10 26 ± 3 28 ± 5
Propionylcarnitine \0.5 \0.5 \0.5 \0.5
Palmitoylcarnitine 15 ± 5 20 ± 3 14 ± 3 19 ± 5
Total carnitine 195 ± 17 207 ± 14 169 ± 20 152 ± 14
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Skeletal muscle oxidative capacity
As expected, maximal respiration rate in the soleus muscle,
a red muscle mainly composed of oxidative fibers, was
higher than in the gastrocnemius, which consists mainly of
glycolytic fibers (Fig. 2). For soleus and gastrocnemius
muscle biopsies, we observed no significant difference in
oxygen uptake between animals treated with carnitine or
acylcarnitines and control animals. These findings indicate
that mitochondrial content and capacity (the activity of
complexes I, II, and IV of the respiratory chain) remained
unchanged in the supplemented compared to the control
group.
Skeletal muscle histology
As illustrated in Fig. 3a, we observed no difference in
muscle fiber-type composition in soleus and gastrocnemius
muscles of treated as compared to control animals. In
soleus muscle, type I fibers represented about 70 % of the
fibers in all treatment groups studied (Fig. 3b).
Exhaustive exercise
As shown in Fig. 4, the mean running distance until
exhaustion of control mice was 561 ± 61 m (n = 6). The
distance covered by treated mice was by trend increased in
all the groups but no statistical significance was observed
because of high interindividual variability (carnitine
699 ± 108 m, acetylcarnitine 772 ± 117 m, propionyl-
carnitine 820 ± 214 m). After pooling all treated animals,
the running distance was 764 ± 84 m (n = 18) and also
not significantly different from the control group. Perfor-
mance of the animals was in the range of 67–70 mW and
was not different between the groups.
Energy metabolism parameters in plasma and skeletal
muscle at rest and after exhaustive exercise
As shown in Table 4, plasma lactate levels increased sig-
nificantly with exercise in all groups, indicating that the
mice exercised above the lactate threshold. The lactate
concentrations after exercise were significantly lower in the
Table 2 Urinary excretion of carnitine, acetylcarnitine (Acetyl-Cn), propionylcarnitine (Propionyl-Cn), and total carnitine
Control Carnitine Acetyl-Cn Propionyl-Cn
Free carnitine 19 ± 2 356 ± 71* 335 ± 68* 360 ± 34*
Acetylcarnitine 2 ± 0 41 ± 10* 54 ± 13* 46 ± 6*
Propionylcarnitine \0.5 1.0 ± 0.3* 1.1 ± 0.3* 3.3 ± 1.1*
Total carnitine 24 ± 4 417 ± 143* 390 ± 76* 448 ± 36*
Excreted amounts are mean values ± SEM of six animals, given in lmol/kg/day
* p \ 0.05 compared to control group
Table 3 Carnitine bioavailability and biosynthesis
Treatment groups
(n = 6)
Intake
(lmol/kg bw/day)
Tissue
accumulation
(lmol/kg bw/day)
Excretion (lmol/kg bw/day) Bioavailability
(%)
Biosynthesis
(lmol/kg bw/day)
Water Food
Control 0 ± 0 9.7 ± 0.5 0.28 ± 0.04 24 ± 4 n.a. 22.4 ± 0.1
Carnitine 2,100 ± 26* 10.1 ± 0.7 0.31 ± 0.05 417 ± 143* 19.8 ± 0.3 n.a.
Acetyl-Cn 2,102 ± 78* 9.4 ± 0.8 0.35 ± 0.08 390 ± 76* 18.6 ± 0.7 n.a.
Propionyl-Cn 2,338 ± 46* 10.1 ± 0.1 0.41 ± 0.05 448 ± 36* 19.1 ± 0.4 n.a.
Carnitine intake by water and food was determined as described in Methods. Carnitine tissue accumulation was calculated based on the carnitine
content in skeletal muscle and the increase in skeletal muscle weight over 28 days. Carnitine excretion was determined in the 24-h urine of the
animals. The bioavailability (F) of carnitine and acylcarnitines was calculated as carnitine by solving Eq. (2) for F and assuming that carnitine
biosynthesis is  carnitine ingestion by food and water and can therefore be neglected [22]. Carnitine biosynthesis was calculated by solving
Eq. (2) for carnitine biosynthesis and using the previously determined value for carnitine bioavailability in mice treated with carnitine. Values are
given as mean ± SEM for 6 animals
bw body weight, n.a. not available
* p \ 0.05 versus control mice. There were no significant differences among the groups treated with carnitine or acylcarnitines
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combined supplemented groups compared to the control
group. Plasma creatine kinase activity was not different
between supplemented and control animals and showed a
slight elevation with exercise compared to resting condi-
tions (results not shown).
Energy parameters were determined in separate samples
of white and red quadriceps femoris (Table 4). Creatine
concentrations were not different between supplemented
and control groups, and were also not significantly influ-
enced by exercise in both red and white quadriceps.
Phosphocreatine concentrations increased by trend with
exercise in red quadriceps and decreased in white quadri-
ceps. The ATP concentrations were not influenced by
exercise, neither in red, nor in white quadriceps. In red
quadriceps, they were by trend higher in supplemented
mice, reaching statistical significance for the combined
supplemented groups both under resting conditions and
after exhaustive exercise. Exercise was associated with a
significant decrease in the glycogen content in white fibers
of control animals and the combined supplemented ani-
mals, while it did not affect the glycogen content in red
muscle fibers. After exercise, the glycogen content was
approximately doubled in supplemented compared to
control animals, reaching statistical significance for the
combined supplemented mice.
Discussion
In contrast to reports in humans [32, 44], acetylcarnitine and
propionylcarnitine showed no significant bioavailability as
parent substance in mice. Both acylcarnitines were hydro-
lyzed before reaching the systemic circulation; as shown for
propionylcarnitine, hydrolysis took place at least partially in
the liver. These findings are in agreement with a study in
pigs, also showing that most orally administered acetylcar-
nitine is hydrolyzed before reaching the systemic circulation
[15]. Bioavailability, estimated as the excess urinary excre-
tion of total carnitine, was in the range of 19 % for carnitine
and also for the two acylcarnitines investigated. This value is
in close agreement with the 14–18 % reported for carnitine
in humans [36, 37]. It is important to realize that the carnitine
excretion pattern was almost identical (15- to 20-fold
increase in the excretion of total carnitine, approximately
15 % as acetylcarnitine and \1 % as propionylcarnitine)
irrespective of the carnitine species administered. At least for
propionylcarnitine, this means that the compound is taken up
by tissues, hydrolyzed to carnitine, and then partially acet-
ylated. This agrees well with studies in which labeled pro-
pionylcarnitine was administered intravenously to rats [13].
Thirty minutes after the injection, the labeled plasma carni-
tine pool contained \10 % propionylcarnitine, but
Fig. 2 Oxygen consumption by isolated muscle fibers. No differences were observed between carnitine or acylcarnitine supplemented mice and
control mice. Data are represented as mean in pmol O2/s/mg protein ± SEM of six animals
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approximately 15 % acetylcarnitine and 80 % carnitine.
Similarly, in humans treated with oral carnitine, elevated
concentrations of acetylcarnitine and propionylcarnitine
have been observed in plasma and urine [10]. Furthermore, in
patients with end-stage renal failure undergoing hemodial-
ysis, intravenous administration of carnitine was associated
ControlA
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soleussoleussoleus
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B
Fig. 3 Histochemical determination of muscle fiber-type composi-
tion. a Representative ATPase and hematoxylin/eosin (H/E) staining
of soleus and gastrocnemius (GC) biopsies. b In soleus muscle, we
observed no difference in muscle fiber-type composition between
treated and control animals. Mean values ± SEM of six animals are
represented
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with increased plasma concentrations of many acylcarnitines
and increased elimination of acylcarnitines by dialysis [41].
These findings provide evidence for an intense exchange
between the plasma and tissue carnitine pools. In tissues,
carnitine can be acylated (depending on the cellular acyl-
CoA pool), transported back into plasma as acylcarnitine and
eventually be excreted via the urine.
The current investigation is in agreement with other
animal studies reporting that oral supplementation of car-
nitine or acetylcarnitine has no significant impact on the
skeletal muscle carnitine content. In rats, low oral doses of
carnitine or acetylcarnitine (200 lmol/kg/day) for 14 days
did not increase the skeletal muscle carnitine pool [24]. In
mice, a carnitine dose of 200 mg/kg/day (approximately
1 mmol/kg/day) for 5 weeks also failed to show an effect
on the skeletal muscle carnitine pool [34]. In contrast,
several studies in rats have shown that the skeletal muscle
carnitine content can be increased with oral carnitine
supplementation [2, 12, 21, 29, 40]. The reasons for the
divergent findings regarding the effect of exogenous car-
nitine on the skeletal muscle carnitine pool are so far not
clear; important variables may be the skeletal muscle car-
nitine content before the administration of exogenous car-
nitine [12, 40] and nutritional factors.
To the best of our knowledge, data concerning oral
bioavailability were so far lacking for propionylcarnitine.
In humans, propionylcarnitine can be absorbed intestinally
and can reach the systemic circulation [44]. However, after
a single dose of 500 mg, the plasma concentration was only
doubled (from 0.3 to 0.6 mM), suggesting a low bioavail-
ability as propionylcarnitine. In the current study, we also
observed a doubling of the plasma propionylcarnitine
concentration, but this increase did not reach statistical
significance. Although the propionylcarnitine concentra-
tion was higher in plasma than in skeletal muscle of the
mice supplemented with propionylcarnitine, we did not
observe an increase in the skeletal muscle propionylcarni-
tine and/or total carnitine concentration. Obviously, even
higher plasma propionylcarnitine concentrations would be
necessary to have an impact on the skeletal muscle carni-
tine pool. As suggested by the current study, such con-
centrations could only be reached by parenteral
application.
Consistent with our findings in the current study, sup-
plementation with high doses of carnitine or acylcarnitines
had no influence on muscle fiber-type composition also in
other studies [11]. This is in contrast to recent findings in
obese Zucker rats, where oral supplementation of carnitine
not only increased the skeletal muscle carnitine content,
but also prevented the obesity-associated shift from type I
to type II muscle fibers [12]. In agreement with the lacking
effect on skeletal muscle morphology in the current study,
treatment with carnitine or acylcarnitines had also no
significant impact on oxygen consumption by and mito-
chondrial function in isolated skeletal muscle fibers
(Fig. 2). These findings agree with most studies in humans
in which the effect of oral carnitine supplementation on the
total muscle carnitine content and on physical performance
has been assessed [4, 43]. On the other hand, the results of
the current study disagree with two studies in long-distance
runners, in which oral supplementation of 2 g of carnitine
per day for 1 month was associated with an approximately
10 % increase in the skeletal muscle carnitine content and
with an increased activity of mitochondrial enzymes,
including complexes of the respiratory chain [1, 19]. An
explanation for these discrepancies may be interactions
between nutrition and expression of the carnitine carrier
OCTN2. It is well established that carnitine supplementa-
tion in humans treated with a high amount of carbohydrates
can increase skeletal muscle carnitine content and physical
performance due to increased expression of OCTN2 [39,
45]. In addition, PPARa has been reported to be a regulator
of OCTN2 expression, suggesting that also lipids may
affect carnitine transport into tissues [46].
Surprisingly, despite the lacking effect of carnitine or
acylcarnitine supplementation on the skeletal muscle car-
nitine pool, carnitine supplementation was associated with
a lower plasma lactate concentration and a better mainte-
nance of the glycogen stores in white skeletal muscle after
exhaustive exercise (Table 4). Lower post-exercise blood
lactate concentrations have recently also been reported in
humans treated with 4.5 g glycine propionylcarnitine
before exercise [20]. These findings indicate that the ani-
mals supplemented with carnitine or acylcarnitines toler-
ated exhaustive exercise metabolically all in all better than
the control animals. This may at least partially explain the
beneficial effects of carnitine supplementation on physical
recovery after intense exercise [42]. In a review about the
pharmacokinetics and metabolism of carnitine and acetyl-
carnitine, Rebouche [36] asked the question whether an
increased carnitine content in target tissues is necessary for
a pharmacological effect of carnitine or whether an
increased exchange between the plasma and tissue carni-
tine pools could be sufficient. As discussed above, the
current study provides evidence that there is an intense
exchange between the plasma and tissue carnitine pools.
The current study also suggests that an increase in the
plasma carnitine pool may be sufficient to influence certain
metabolic pathways in skeletal muscle, e.g., lactate pro-
duction and glycogen breakdown. The molecular mecha-
nisms responsible for this effect remain speculative,
however. One possibility is the export of potentially toxic
acyl groups from skeletal muscle, as shown in patients on
hemodialysis supplemented with carnitine [41]. Another
possibility is an effect of carnitine and/or acylcarnitines on
capillary endothelial cells, possibly resulting in
Eur J Nutr (2014) 53:1313–1325 1323
123
vasodilation and improved skeletal muscle perfusion and
nutrient supply during high-intensity exercise [20].
Conclusions
Oral supplementation of carnitine, acetylcarnitine, or pro-
pionylcarnitine is associated with increased plasma con-
centrations of total carnitine and increased urinary
excretion of carnitine, but does not affect the skeletal
muscle carnitine content. Skeletal muscle morphology,
oxidative capacity, and physical performance are also not
affected by long-term carnitine supplementation. On the
other hand, white skeletal muscle glycogen stores were
maintained better and plasma lactate concentrations were
lower in supplemented animals after exhaustive exercise,
indicating that mice with carnitine supplementation could
achieve the same physical performance as control mice
with less metabolic perturbance.
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